AstraZeneca’s COVID-19 vaccines listed for emergency use by WHO
The Emergency Use Listing will allow doses of the COVID-19 vaccines to be distributed through COVAX, the WHO’s vaccine allocation facility.
List view / Grid view
The Emergency Use Listing will allow doses of the COVID-19 vaccines to be distributed through COVAX, the WHO’s vaccine allocation facility.
The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results.
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
The smart syringe market should grow due to increasing public awareness surrounding vaccination and the increasing popularity of safety injection devices with manufacturers and healthcare professionals.
COVAX has allocated 90 million doses of AstraZeneca’s COVID-19 vaccine and 320,000 doses of the Pfizer-BioNTech vaccine to African countries.
A preliminary analysis suggests the COVID-19 Vaccine AstraZeneca was 74 percent effective after the first dose and 82 percent effective with a 12-week inter-dose interval.
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV∆G-ZEBOV-GP, live, free of charge.
The President of the US, Joe Biden, has written a letter to the UN announcing his intention for the country to remain a part of the WHO.
A novel algorithm shows that there is a robust network for transferring plasmids between bacteria which may be causing the rapid spread of antibiotic resistance.
Moderna's COVID-19 vaccine has been approved in the EU with a conditional marketing authorisation by the European Commission.
As the global COVID-19 response continues, so does the rapidly expanding pipeline for a novel COVID-19 vaccine. Here, experts from Avalere Health outline ongoing US and global vaccine development efforts, including the role of public-private partnerships in accelerating vaccine development. They will also focus on the broader context of respiratory…
The UK Government is supporting the development of COVID-19 vaccines, including two innovative UK vaccine candidates. In this article, we describe the history of these candidates and introduce innovative small and medium enterprises (SMEs) and national capabilities that are working to combat the current pandemic and improve the UK’s vaccine…
A clinical trial has shown that nOPV2 has the potential to overcome outbreaks caused by a mutated polio strain linked to the Sabin vaccine.
Alzheimer’s and diabetes enter the top ten global causes of death for the first time, while HIV/AIDS and tuberculosis deaths fall, according to the WHO’s 2019 Global Health Estimates.